Boehringer Ingelheim

This study looks at how well the drug Jardiance works compared to usual heart failure treatments in 5,000 adults in China with a type of heart failure called HFrEF. The goal is to see if Jardiance reduces the risk of death from heart problems or hospital stays for heart failure. …

This study tests a medicine called nerandomilast in adults with a type of lung scarring (fibrosing ILD) that is not IPF. The goal is to see if it can slow down worsening of lung function over a year. About 466 participants will receive either the drug or a placebo, and doctors wi…

This study tests a new oral medication called nerandomilast for people with systemic sclerosis (scleroderma), a disease that causes skin thickening and organ damage. About 448 adults will be randomly assigned to receive either the drug or a placebo twice daily for up to 4 years. …

This study tests nerandomilast, a medicine already approved for adults with lung scarring, in children aged 2 to 17 with fibrosing interstitial lung disease. About 35 children will take the drug or a placebo for 6 months, then all receive the drug for at least 2 years. Researcher…

This early-stage study tests the drug verducatib in 12 healthy Chinese adults aged 18-55. Participants take the drug by mouth daily for 4 weeks so researchers can measure how the body processes it and check for side effects. The goal is to gather safety and dosing information to …

This study looks at how a medicine called BI 3000202 is handled by the body in people with and without liver problems. About 44 adults aged 18 to 80 will take one tablet of the medicine. Researchers will measure the drug levels in the blood and check for side effects over about o…

This early-stage study tests a new drug called BI 3821001 in 72 healthy men aged 18 to 55. The goal is to check if the drug is safe and how the body processes it. Participants receive either a single rising dose of the drug or a placebo. The study is not yet recruiting.

This study will observe about 3,000 adults in China with heart failure with preserved ejection fraction (HFpEF) who are starting the drug Jardiance. Researchers will track how often patients are hospitalized for heart failure or die from heart-related causes. The goal is to see h…